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Abstract
Anti-citrulline immune responses contribute to rheumatoid arthritis (RA) development, and
are linked with the expression of HLA-DR molecules that encode the Shared Epitope (SE).
Immune responses to homocitrulline, a structural analog of citrulline, have been recently
detected in RA, but their role in RA is unknown.
The objectives of this study were to examine the specificity of anti-homocitrulline antibodies
for RA, the dependence of anti-homocitrulline responses on SE-expression, and the crossreactivity of responses to homocitrulline and citrulline. These objectives were addressed in
RA patients and in SE-expressing DR4tg mice using homocitrulline- and citrulline-rich
peptides.
Anti-homocitrulline antibodies occurred specifically in RA. The SE was associated with the
development of immune responses to homocitrulline and cross-reactivity to citrulline in
homocitrullinated peptide-immunized mice.

Anti-homocitrulline and anti-citrulline

antibodies were cross-reactive in RA patients and DR4tg mice, and the responses to
homocitrulline- and citrulline-containing peptides were immunologically related.
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Chapter 1

1

Rheumatoid arthritis

1.1 Overview
Rheumatoid arthritis (RA) is one the most prevalent chronic inflammatory diseases and is
estimated to affect up to 1% of the population worldwide (1,2). RA is an autoimmune
disorder which can often result in irreversible damage to bone and cartilage tissue. This
leads to a progressive loss of joint function and often results in disability in RA patients.
RA is a debilitating disease associated with a decreased quality of life, high economic
burden (2,3), and an increased rate of mortality compared to the general population (4,5).
RA is a complex disorder and susceptibility to disease has been reported to be affected by
various factors. In RA, similar to other autoimmune diseases, there is a gender bias. The
prevalence of RA is greater in women, and gender may also affect the disease course (6).
Susceptibility to RA is influenced by environmental exposures (7), and especially with
smoking which has been associated with a heightened incidence of RA (8). Genetics also
modify the risk of RA (9) and genes, such as those coding for major histocompatibility
antigens (especially Shared Epitope (SE)-encoded HLA-DRB1) can predispose
individuals to develop RA.
RA is systemic in nature, and has been shown to affect various organ systems.

The

joints, skin, cardiovascular system and lungs are a few examples of the tissues that can be
affected by RA (10). The mechanism by which RA affects these various tissues is not
well understood. Joint inflammation, which is the primary manifestation of RA, often
involves the large-scale infiltration of leukocytes into the joint tissue and proinflammatory changes to the environment of the joint (11). These changes are mediated
by cells of both the innate and adaptive immune system; various immune cells such as
dendritic cells, macrophages, neutrophils, T and B cells are present in the synovial tissue
of RA patients (12–14). Amongst the changes that occur in the synovial tissue are
increased expression of inflammatory cytokines including TNFα, IL-6, IL-17, and type I
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interferons (15) as well as matrix metalloproteinases (16), which contribute to the
degradation of bone and cartilage in RA. Additionally, phenotypic changes occur in
joint-resident cell types including fibroblast-like synoviocytes which normally play a role
in maintaining the synovial fluid (17), and osteoclasts which function in bone resorption,
thereby promoting the dysfunction and degradation of the joint (11).
The etiology of RA is currently unknown and thus, targeted treatments for RA are
unavailable.

Instead, strategies for the treatment of RA employ disease-modifying

antirheumatic drugs, glucocorticoids and biologics (18). Some of these therapeutics,
methotrexate and cortisol for example, are immunosuppressive and have inhibitory
effects on the immune system.

Other therapeutics have been developed that target

inflammatory cytokines such as TNFα (19), immune cells including B (20) and T (21)
cells, as well as immune signaling pathways (22). These current treatment options for
RA have broad effects on immune system functions and as a result, are accompanied with
risks of side-effects including increased risk of infection and cardiovascular disease (23–
25). To more specifically treat RA, further study of the mechanisms underlying the
disease is required.
The disease process in RA is often associated with autoantibodies which predicts disease
and are believed to participate in RA pathogenesis. The importance of autoantibodies in
RA is underscored by the classification of patients as seropositive or seronegative
depending on the expression of autoantibodies; seropositive and seronegative RA patients
often differ in disease patterns (ie. disease severity and outcome). In RA, one of the
major autoantibodies is rheumatoid factor (RF), an autoantibody which targets IgG and is
diagnostic for RA. Anti-citrulline antibodies, which are antibodies that bind to antigens
containing citrulline, are another class of antibodies that are frequently found in RA
patients (26–29). Anti-citrulline antibodies are also a diagnostic biomarker for RA and
are measured clinically as anti-cyclic citrullinated peptide antibodies (anti-CCP). Several
other autoantibody systems have been identified in RA patients, including autoantibodies
reactive to proteins that have been modified post-translationally by acetylation and by
formation of malondialdehyde-acetaldehyde adducts (30,31).

Recently, anti-

homocitrulline antibodies have been detected in RA patients and have garnered much
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interest as a potential biomarker for disease. Whether anti-homocitrulline antibodies
have a role in RA pathogenesis remains to be determined.

1.2 Risk factors for RA
RA is a multifactorial disorder and the triggers that initiate the disease are poorly
understood. A study of monozygotic twins by MacGregor et al. estimated the overall
heritability of RA (seropositive and seronegative disease) to be 60% (9), indicating that
genetic risk factors play a substantial role in RA development. Environmental exposures
have been reported to be important contributors to RA risk (7,32). The susceptibility to
RA is believed to be an interaction between both genetic and environmental risk factors.
As previously mentioned, RA patients with and without autoantibodies are
phenotypically different; the complicated nature of RA development is further
highlighted by the findings that both genetic (33–35) and environmental (32) risk factors
differ between anti-CCP-positive and anti-CCP-negative RA.

1.2.1

Smoking

The most characterized environmental risk factor for RA is smoking. Meta-analyses by
Sugiyama et al. (8) and Di Giuseppe et al. (36) have provided evidence that smoking
increases the incidence of RA. Moreover, the risk of RA is increased for years even after
smoking cessation (37).

The mechanisms by which smoking contributes to RA

development is not clear, though several possibilities have been previously described
(38).

Smoking induces a pro-inflammatory state that may induce oxidative stress,

cellular apoptosis and changes in cytokine expression, among many other effects (38). In
particular, smoking has been linked to increased TNFα activity (39) which is known to
mediate RA pathogenesis.
Notably, smoking has been linked to anti-CCP-positive, but not anti-CCP-negative RA.
Studies by Kallberg et al. (40) and Linn-Rasker et al. (41) have found associations
between smoking and expression of anti-CCP (as well as SE-encoded HLA-DRB1),
which emphasizes the contribution of smoking to the development of anti-citrulline
immune responses.

This is supported by evidence that smoking promotes the
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citrullination of self-proteins in the lungs by upregulating the expression of an enzyme
(peptidylarginine deiminase) that catalyzes protein citrullination (42,43), as well as the
finding of citrullinated proteins in lung tissue (44). Smoking has also been linked to
protein carbamylation, which could result in the generation of homocitrulline-containing
antigens (45).

These antigens may help in triggering the development of anti-

homocitrulline antibodies and may also be targets for the autoimmune response.
However, Jiang et al. did not find an association between anti-homocitrulline antibodies
and smoking in RA patients that were negative for anti-CCP (46).

1.2.2

Periodontal disease

Periodontal disease is a common inflammatory disease that has been associated with antiCCP-positive RA. Both of these diseases share some similar risk factors including
smoking and expression of HLA-DR4 alleles (47). Compared to the general population,
patients with RA are at a higher risk of developing periodontal disease and vice-versa
(48). Moreover, RA patients are more likely to develop more severe periodontal disease
(48).
Porphyromonas gingivalis is a bacteria that is often found in dental plaque. P. gingivalis
has been identified as a major pathogen in periodontal disease and antibodies against this
pathogen have also been detected in patients with RA (49,50). Moreover, Kinloch et al.
demonstrated that α-enolase from P. gingivalis is arthritogenic in a mouse model of RA
(DR4tg mice) (51). P. gingivalis expresses several virulence factors that enable the
pathogen to survive and colonize in host tissue. Among these are a class of extracellular
cysteine proteases known as gingipains, which can subvert the host immune response and
promote inflammation (52). P. gingivalis also expresses a peptidylarginine deiminase
which is capable of citrullinating host proteins (53–55), and thereby may initiate anticitrulline immune responses in RA-susceptible individuals that express SE-encoded
HLA-DR molecules.
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1.2.3

Shared Epitope

The expression of certain class II MHC molecules play an important role in susceptibility
to RA. Genes coding for HLA-DR have been known risk factors since the work of
Stastny (56,57). He identified that RA patients shared a common MHC class II haplotype
(57). In 1987, Gregersen et al. from the Winchester lab posed the Shared Epitope
hypothesis to explain the association of several HLA-DRB1 alleles with RA (58). They
demonstrated that RA-associated alleles of HLA-DRB1 (including *0401, *0404, *0405,
*0408, *0413, *0101, *0102, *1402, and *1001) encode for a conserved amino acid
consensus sequence: QKRAA, QRRAA, or RRRAA (58).

The SE is encoded at

positions 70-74, located in the third hypervariable region of the N-terminal domain of the
HLA-DRβ chain (58) and forms the P4 peptide-anchoring pocket of HLA-DR (58,59).
Alleles encoding for SE-encoded HLA-DR molecules are highly prevalent in RA
patients, are reported to be expressed in approximately 75% of RA patients (60–62) and
have also been associated with more severe disease (63).
The SE is believed to participate in the pathogenesis of RA. One mechanism by which
the SE is believed to contribute to RA development is through the presentation of
citrullinated peptides by antigen presenting cells that express SE-positive HLA-DR
molecules, leading to the initiation of anti-citrulline immune responses. The evidence
that SE-encoded HLA-DR binds to citrullinated peptides was first reported by Hill et al
(64). They demonstrated that a citrullinated peptide derived from vimentin bound to SEpositive HLA-DRB1 molecules encoded by the alleles *0101, *0401 and *0404, but not
to several SE-negative HLA-DRB1 molecules (64). This was subsequently confirmed
by the work of Scally et al. who reported on crystal structures of HLA-DRB1*0401
complexed to four citrullinated epitopes derived from vimentin and aggrecan (59).
Moreover, Huizinga et al. found the SE to be a risk factor for anti-CCP-positive RA, but
is not associated with anti-CCP-negative disease (65), in keeping with the original
findings by Hill et al (64). Additionally, in a mouse model of RA that is transgenic for
human HLA-DR4 (DR4tg mice), Hill et al. showed that immunization with citrullinated
fibrinogen induced citrullinated fibrinogen-reactive T and B cell responses as well as
inflammatory arthritis (66).
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Besides the involvement in the anti-citrulline immune response, the SE has been shown
to also act as a signal transduction ligand. Ling et al., from the Holoshitz lab, showed
that the SE acts as a ligand that increased production of nitric oxide, resulting in higher
oxidative stress (67,68). This was later identified to be mediated through the binding of
the SE to cell surface calreticulin (69,70). This signalling event has been shown to have
various consequences that may contribute to RA pathogenesis. Almeida et al. from the
same group, demonstrated that SE-activated signalling in dendritic cells induced a Th17polarizing response (71), which is associated with autoimmunity. In another study by
this group, Holoshitz et al. reported that SE-mediated signalling is able to induce
osteoclastogenesis and promote the degradation of bone tissue (72). Recently, they also
showed that the SE is associated with spontaneous skeletal bone damage in DR4tg mice
(73). The observations of Holoshitz and colleagues suggest that the SE may be involved
in the development of arthritis independent of its role in antigen presentation.

1.2.4

Other genetic risk factors

In addition to genes coding for HLA-DR with the SE, other genetic risk factors have also
been associated with RA susceptibility. One of these non-HLA risk factors is PTPN22,
which encodes for a tyrosine phosphatase that is expressed by leukocytes and functions in
immune system signalling; a polymorphism of PTPN22 has been associated with an
increased risk for developing anti-CCP-positive RA (34,74,75). PADI4, which encodes
for an enzyme that participates in protein citrullination, is another risk locus for RA
development (75,76) and has been associated with radiographic damage (77). Recently, a
genome-wide association study performed by Okada et al. identified approximately 100
loci that modify the susceptibility to RA (78). Many of these loci contain genes related to
immune system functions including T cell signalling, cytokines such as TNFα and IL-6,
and also members of the Janus kinase signalling family (78). Nonetheless the SE is the
most important risk factor for RA (79).
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1.3 Autoantibodies in RA
The breakdown of immunological tolerance to endogenously expressed proteins is often
the first step in the development of autoimmunity. In RA, the disease process results in
the production of autoantibodies and the detection of these antibodies is therefore
important for RA diagnosis. As noted (in 1.1), the presence of autoantibodies in patients
is often a predictor for disease severity in RA. Thus screening for these antibodies is
crucial for the early identification of RA, allowing for therapeutic intervention prior to
the development of potentially irreversible tissue damage.

Further studies of

autoantibody systems in RA is important to understand the mechanisms leading to the
pathogenesis of RA and additionally, to provide clinically relevant information to aid in
the treatment of this disease.

1.3.1

Rheumatoid factor

RFs were the first autoantibodies that were associated with RA and were initially
described in the 1940’s when Waaler (80) and Rose et al. (81) demonstrated that sera
from RA patients could promote the agglutination of sheep red blood cells that were
sensitized with rabbit IgG. RFs are autoantibodies (of several isotypes) that recognize the
Fc portion of human IgG (82), and were included in the diagnostic criteria for RA in
1987 (83). RFs have been shown to be present in approximately 50-65% of patients with
early RA (27,84) and in up to 90% of patients with longstanding disease (84,85).
However, RFs are not specific for RA; RFs have been shown to be found in patients with
other autoimmune diseases as well as in healthy individuals (30,84,86). Despite the
evidence that RFs are not specific for RA, they have been associated with RA activity.
RFs have been reported to predict the development of RA (87) and have been associated
with radiographic progression (88,89).

1.3.2

Anti-citrulline antibodies

Anti-citrulline antibodies (a general term for anti-citrullinated protein/peptide antibodies;
ACPA) are highly characteristic of and are specific for RA. Citrullination is a normal
post-translational process that involves the enzymatic conversion of positively charged
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arginine residues into non-charged citrulline residues (Figure 1.1A). The importance of
this arginine-to-citrulline modification for the binding of peptides to SE-encoded HLADR molecules was first reported in the aforementioned study of the SE by Hill et al. (64)
and was corroborated by the study of Scally et al (59). The process of citrullination is
mediated by the peptidylarginine deiminase (PAD) enzyme family, of which five
isozymes are expressed in humans (90). PAD enzymes are expressed ubiquitously and
can be found in many different cell and tissue types. PAD2 and PAD4 in particular are
expressed by cells of the immune system (90) and have been demonstrated to be in RA
synovial tissue (91–93). It is unknown whether these two PAD isozymes contribute
equally or if one of them is more important in the generation of citrullinated antigens in
RA. The antigen(s) responsible for driving inflammation in RA remains unknown,
though several candidate citrullinated autoantigens have been identified in RA joints
including fibrinogen (94), vimentin (95,96), type II collagen (97) and α-enolase (92,98).
Schellekens et al. were the first to identify that citrulline was the target of anti-citrulline
antibodies (99). Prior to this report, these RA-associated autoantibodies were described
as anti-perinuclear factor (100), anti-keratin antibodies (101) and anti-filaggrin antibodies
(102). As previously noted, anti-citrulline antibodies are commonly measured clinically
using cyclic citrullinated peptide(s) (CCP) and have been included as a diagnostic marker
for RA alongside RF (103). These antibodies are detected in approximately 70% of RA
patients and are almost 100% specific for RA (26,104,105). Further, anti-CCP have been
shown to precede the onset of arthritic symptoms as well as predict RA development
(29,106,107). Anti-citrulline antibodies are also believed to be arthritogenic because RA
patient sera (108) and purified human IgG anti-citrulline antibodies (109) have been
reported to induce arthritis in young FcγRIIB-deficient mice.

1.3.3

Anti-homocitrulline antibodies

Anti-homocitrulline antibodies (a general term for anti-homocitrullinated protein/peptide
antibodies; AHCPA), also known as anti-carbamylated protein antibodies (anti-CarP), are
a family of antibodies that were reported to be associated with RA in 2010. Turunen et
al. showed that the immunization of rabbits with homocitrullinated albumin and type I
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Figure 1.1. Citrullination and homocitrullination. The post-translational conversion
of arginine to citrulline (citrullination; A) and the conversion of lysine to homocitrulline
(homocitrullination; B). The chemical structures of homocitrulline and citrulline are
similar.

The difference between these residues is that homocitrulline possesses an

additional carbon in its side chain (red arrow).
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collagen induced RA-associated autoantibodies (110). Also, evidence that homocitrulline
may play a role in RA pathogenesis was reported by Mydel et al., who demonstrated that
homocitrulline-containing peptides derived from filaggrin induced inflammatory arthritis
in mice (111). The susceptibility to arthritis in these mice varied depending on the strain,
suggesting that the susceptibility to arthritis is influenced by the MHC class II haplotype
(111).
Anti-homocitrulline antibodies are frequently detected in RA patients and have garnered
interest as a potential biomarker for RA. However, the anti-homocitrulline immune
response remains poorly understood in RA. The genetic factors (eg. HLA-DR) that
contribute to this response have not been characterized. The in vivo antigenic target of
these antibodies is unknown and as a consequence, different systems of homocitrullinated
antigens are currently being used to screen for these antibodies (mentioned in further
detail below).

1.3.3.1

Homocitrulline

Anti-homocitrulline antibodies target proteins/peptides that have undergone a posttranslation process known as homocitrullination (also called carbamylation). In this
process, the ε-amino group of a peptidyl-lysine residue is modified to generate
homocitrulline (45) (Figure 1.1B). Homocitrulline shares a similar chemical structure
with citrulline. Both homocitrulline and citrulline are polar, neutrally-charged amino
acids and both of these residues possess an ureido functional group. The only difference
between citrulline and homocitrulline is that the homocitrulline side chain is extended by
an additional carbon.
The process of homocitrullination is mediated chemically by cyanate, which can be
generated in the body through the spontaneous degradation of urea; cyanate and urea
exist in equilibrium in solution (45). Thus, low levels of cyanate are present under
physiological conditions. Thiocyanate is a metabolite that is elevated in the serum of
smokers (112), and the oxidation of thiocyanate is also able to produce cyanate (45). The
oxidation of thiocyanate has been associated with the activity of myeloperoxidase (45),
which is an enzyme that is abundantly expressed in neutrophils and monocytes. In a
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mouse model of peritonitis (inflammation of the peritoneum), Wang et al. reported higher
levels of homocitrullinated proteins in wild-type mice compared to myeloperoxidasedeficient mice (45) and there is also evidence that myeloperoxidase and homocitrulline
are found in the synovial tissue of RA patients (93). These observations demonstrate an
association between inflammation, homocitrullination and RA.

1.3.3.2

Anti-carbamylated fetal calf serum antibodies

Anti-homocitrulline antibodies were first detected in RA patients in 2011 by Shi et al.
who screened for antibodies reactive to carbamylated fetal calf serum (anti-CarP-FCS)
(113). Fetal calf serum is a mixture of proteins of bovine origin, thus CarP-FCS likely
does not correspond to in vivo homocitrullinated antigens in RA patients. However,
CarP-FCS remains a commonly used antigen for the detection of anti-homocitrulline
antibodies.
The prevalence of anti-CarP-FCS in RA patients is estimated to be 30-45% (46,113–115).
These antibodies are mainly found in patients who are also positive for anti-CCP, but can
also be detected in a small proportion of anti-CCP-negative RA patients (46,113).
Similar to RF and anti-CCP, anti-CarP-FCS can be present in individuals prior to the
onset of RA (116,117), and are also predictive of more severe disease outcomes
(113,118). Anti-CarP-FCS have been shown to also be expressed in other inflammatory
arthritides and connective tissue diseases (114,119–122). This has led to the notion that
anti-CarP-FCS may be a biomarker of inflammation rather than being specific for RA, as
proposed by Reed et al (123). However, the expression of anti-CarP-FCS in other
inflammatory (non-rheumatologic) conditions is yet to be examined.

1.3.3.3

Anti-homocitrullinated fibrinogen antibodies

Homocitrullinated fibrinogen as a candidate protein antigen for anti-homocitrulline
antibodies was first studied by Scinocca et al. (124), based on the evidence that
citrullinated forms of fibrinogen were located in RA synovial tissue (94) and are the
target of anti-citrulline antibodies in RA patients (28,94,125). Scinocca et al. reported
that human fibrinogen is accessible to homocitrullination; 89 of 103 lysines (in
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fibrinogen) were able to undergo homocitrullination in vitro (124).

Anti-

homocitrullinated fibrinogen antibodies have been shown to exist as several isotypes in
RA patients. IgG anti-homocitrullinated fibrinogen antibodies were reported to be the
predominant isotype, having been found in approximately 30-45% of RA patients
(124,126) as well as in up to 20% of first-degree relatives of RA patients (126). The
prevalence of IgM and IgA anti-homocitrullinated fibrinogen antibodies were noted to be
lower, and were present in 20% and 7% of RA patients respectively (126). In addition,
Scinocca et al. reported that anti-homocitrullinated fibrinogen antibodies were highly
specific for RA as these antibodies were not detected in patients with systemic lupus
erythematosus nor in patients with psoriatic arthritis (124).

1.3.3.4
Since

Antibodies to other homocitrulline-containing antigens

anti-homocitrullinated

antibodies

have

been

described,

several

other

homocitrullinated peptide antigens have also been used for antibody screening. So far,
homocitrulline-containing peptides derived from proteins that are commonly found in the
synovial tissue of RA patients have been examined, including vimentin (127), collagen
(128), and α-enolase (123). The frequency of IgG antibodies to these homocitrullinated
peptides in RA patients is approximately 20-35% (123,127,128).

1.4 Immunological relatedness of citrulline and
homocitrulline
Citrulline and homocitrulline are structurally similar amino acids and the idea that these
amino acids are immunologically related was first brought up by Turunen et al. in 2010.
They were the first to show that a commonly employed commercial antibody (also
known as the Senshu antibody) for the detection of citrulline, also recognized
homocitrulline (110).

They also found anti-citrulline antibodies following the

immunization of rabbits with homocitrullinated proteins (110). In contrast, Mydel et al.
found that antibodies to homocitrulline and citrulline in mice were specific for the
homocitrullinated or citrullinated peptide used for immunization (111).
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Human studies have shown that anti-homocitrulline antibodies and anti-citrulline
antibodies are often co-expressed in RA (46,113,114,123).

RA patients frequently

express the SE (60–62), which has been shown to accommodate citrulline and
homocitrulline similarly (124).

This event could initiate citrulline-specific,

homocitrulline-specific or cross-reactive immune responses in RA.

1.4.1

Anti-citrulline and anti-homocitrulline antibody crossreactivity in RA patients

Several studies have examined the cross-reactivity of anti-citrulline and antihomocitrulline antibodies in RA patients (113,123,124,127–129), with varying degrees of
cross-reactivity between these antibodies being reported. The differences in the observed
cross-reactivity between anti-citrulline and anti-homocitrulline antibodies have led to the
two opposing views that these antibodies constitute a single family of antibodies that are
reactive to both citrulline and homocitrulline (cross-reactive), or that anti-citrulline and
anti-homocitrulline antibodies are distinct antibody systems (non-cross-reactive).
The first studies on the cross-reactivity of anti-citrulline and anti-homocitrulline
antibodies in RA patients were conducted by Shi et al., using citrullinated and
homocitrullinated forms of FCS (113) and later, fibrinogen (129). Two studies that were
conducted by Shi et al. found differing levels of cross-reactivity between anti-citrulline
and anti-homocitrulline antibodies, depending on the antigens that they used (113,129).
In one study, they reported that anti-CCP and anti-CarP-FCS were not cross-reactive to
citrullinated and homocitrullinated FCS (113).

In another study, they used

homocitrullinated fibrinogen and they showed that antibodies to this antigen were crossreactive in some RA patients because the binding of these antibodies to homocitrullinated
fibrinogen could be inhibited by citrullinated fibrinogen (129). Using the same antigen
(fibrinogen) and method, Scinocca et al. also showed cross-reactivity of antihomocitrullinated fibrinogen antibodies, but in the majority of RA patients that they
examined (124).
A limitation of these studies however, was the use of modified (homocitrullinated or
citrullinated) proteins as a target of anti-citrulline and anti-homocitrulline antibodies. As
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reported by Scinocca et al. (124), proteins such as fibrinogen differ in the number of
arginine and lysine residues, and this could result in different numbers of citrulline or
homocitrulline residues following each modification.

Differences in the position of

citrulline and homocitrulline in the protein sequence could also affect citrulline and
homocitrulline cross-reactivity because the backbone surrounding these residues are
likely to be different and this could influence antibody binding. Thus, more recent
studies on the cross-reactivity of anti-citrulline and anti-homocitrulline antibodies have
utilized citrulline- and homocitrulline-containing peptides (123,127,128) instead of
proteins. Juarez et al. (127) and Turunen et al. (128) have found only partial overlap in
the specificities of antibodies to citrullinated and homocitrullinated peptides of vimentin
and collagen, whereas Reed et al. (123) showed significant cross-reactivity using a
peptide of α-enolase. Thus, the evidence of the relatedness of anti-citrulline and antihomocitrulline antibodies is controversial, and the identity of these antibodies as a single
(cross-reactive) or discrete (non-cross-reactive) antibody families remains unresolved.

1.4.2

Anti-citrulline and anti-homocitrulline antibody crossreactivity in animal models

Evidence of cross-reactive citrulline and homocitrulline immune responses in
experimental animal models has been explored by only two groups. Turunen et al.
examined the cross-reactivity of citrulline and homocitrulline immune responses in
rabbits

(110,130).

They showed that rabbits that were immunized with

homocitrullinated proteins (albumin and type I collagen) generated antibodies to the
proteins used in immunization as well as antibodies to citrullinated antigens, including
CCP, citrullinated vimentin and citrullinated telopeptides of type I and type II collagen
(110,130).

In some of these rabbits, the antibody binding to citrulline-containing

peptides of type I collagen could be inhibited by similar peptides which contained
homocitrulline residues instead of citrulline (110,130). Similarly, the immunization of
rabbits with citrullinated peptides (derived from type I and type II collagen) generated
antibodies to citrullinated and homocitrullinated peptides (130). Thus these studies by
Turunen et al showed that anti-citrulline and anti-homocitrulline antibodies are crossreactive.
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Mydel et al. examined the cross-reactivity of anti-homocitrulline and anti-citrulline
immune responses in mice (111).

They showed that mice immunized with a

homocitrullinated filaggrin peptide developed antibodies to this homocitrullinated
peptide, but which did not cross-react with its citrullinated counterpart. These mice also
developed arthritis when given intra-articular injections of citrullinated filaggrin peptide
despite not having antibodies to this antigen. The mechanism underlying the induction of
arthritis in these mice is not known.

1.5 Rationale, hypothesis and objectives
RA is associated with immune responses to citrulline and more recently, with antihomocitrulline immune responses. Homocitrulline is structurally similar to citrulline,
thus these amino acids may be recognized similarly by the immune system.
In RA patients, studies on the relatedness of anti-citrulline and anti-homocitrulline
antibodies have reported discrepant findings on the cross-reactivity of these antibodies.
The degree of cross-reactivity has been found to differ depending on the antigen of study
(113,123,124,127–129). In experimental animal models, cross-reactive anti-citrulline
and anti-homocitrulline immune responses have been shown in rabbits (110,130) but not
in mice (111). Thus the relatedness of the anti-citrulline and anti-homocitrulline immune
response remains controversial.
In addition, immune responses to citrulline have been associated with the SE, the
strongest genetic risk factor for RA (79). SE-encoded HL-DR molecules have been
reported to bind to citrulline-containing peptides, resulting in T and B cell responses to
these antigens in DR4tg mice (66). It is unknown whether the SE plays a similar role in
the development of anti-homocitrulline immune responses.
This study attempts to address some of these issues using RA patients and in a mouse
model of RA (DR4tg mice). We examined the anti-homocitrulline and anti-citrulline
immune response using a synthetic homocitrulline-rich peptide, HomoCitJED, and its
citrulline-containing counterpart, CitJED. These peptides share the same number of
homocitrulline or citrulline residues and share the same peptide backbone.
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The hypothesis of this study is that the anti-homocitrulline and anti-citrulline immune
responses are related and are specific for RA. Anti-homocitrulline and anti-citrulline
antibodies are cross-reactive and their expression is dependent on the SE.
To test this hypothesis, the objectives of this study are to examine:
i)

The frequency and specificity of antibodies to a homocitrulline-containing
peptide (HomoCitJED) and its citrulline-containing counterpart (CitJED) in
RA patients.

ii)

The cross-reactivity of these antibodies to HomoCitJED and CitJED in RA
patients.

iii)

The development of T and B cell responses to HomoCitJED in (SE-positive)
DR4tg mice and (SE-negative) wildtype B6 mice following immunization
with HomoCitJED.

iv)

The cross-reactivity of the immune responses in HomoCitJED-immunized
DR4tg and B6 mice.
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Chapter 2

2

Relatedness of antibodies to peptides containing
homocitrulline or citrulline in patients with rheumatoid
arthritis

This chapter is under review for publication in The Journal of Rheumatology.

2.1 Introduction
Rheumatoid arthritis (RA) is an inflammatory autoimmune disorder that predominantly
affects the joints and is specifically associated with anti-citrullinated protein/peptide
antibodies (ACPA) (1–4). Recently, anti-homocitrullinated protein/peptide antibodies
(AHCPA), also known as anti-carbamylated protein antibodies (anti-CarP) have been
identified in RA patients (5–9). Both ACPA and AHCPA can occur prior to disease
onset (6,10,11) and are predictive of more severe disease (8,12). ACPA have been
demonstrated to be arthritogenic (13,14); the role of AHCPA in RA pathogenesis is
unknown.
ACPA and AHCPA target citrullinated and homocitrullinated antigens, which arise from
the post-translational modification of arginine and lysine respectively. Citrulline and
homocitrulline have identical chemical structures, except homocitrulline has an additional
carbon (15). Studies show that ACPA can detect proteins containing homocitrulline
(5,16). However, the degree of cross-reactivity of ACPA for homocitrullinated proteins
varied between the studies. These discrepancies may be due to proteins having different
numbers and locations of citrulline and homocitrulline, as we have previously reported
for fibrinogen (5), potentially resulting in different peptide antigens.

Studies using

citrulline and homocitrulline-containing peptides with the same backbone were
inconclusive because the affinity of antibodies to citrullinated and homocitrullinated
peptides were not investigated (17–19).
In this study, we used a synthetic citrulline-rich peptide, JED (referred to here as CitJED)
and its homocitrullinated counterpart (HomoCitJED).

These peptides have a high
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proportion of citrulline and homocitrulline residues (9/18) rendering immune reactivity to
the backbone unlikely.

Although not derived from an endogenously expressed

autoantigen, we showed that CitJED captures clinically relevant antibody reactivities
from RA patients (anti-cyclic citrullinated peptide and anti-citrullinated fibrinogen
antibodies) (5).

Herein we employed CitJED and HomoCitJED to examine the

expression, relatedness and relative affinity of antibodies to citrullinated and
homocitrullinated peptides in RA patients.

2.2 Materials and methods
2.2.1

Study population

Serum samples were collected from healthy subjects, and from RA patients attending a
tertiary care Rheumatology clinic at St. Joseph’s Health Care London (SJHC; London,
ON, Canada). All RA patients (n=137) satisfied the American College of Rheumatology
2010 criteria for RA (20) and all were treated with disease-modifying antirheumatic
drugs. The swollen joint count in RA was determined by the treating rheumatologist who
performed a 64 joint examination; only swollen joints attributed to active RA were
included in the count. RA patients without joint swelling were considered to be in
remission.

Demographic, serological and clinical characteristics of RA patients are

summarized in Table 2.1. Healthy subject serum samples (n=51) were collected from
accompanying individuals who were unrelated to the RA patients, and from staff
members at SJHC or The University of Western Ontario (London, ON, Canada). Healthy
subjects were 65% female with a median age of 45 years (range 21-74). Healthy subjects
did not have autoimmune disease, and were excluded from the study if they had a history
of joint symptoms.
Systemic Lupus Erythematosus (SLE) and Psoriatic Arthritis (PsA) patients were
previously described (5).

SLE patient serum samples were collected from patients

attending SJHC (n=37).

All of these patients satisfied the American College of

Rheumatology criteria for SLE (21). SLE patients were 89% female with a mean age of
53 years (range 24-81). Of the 37 SLE patients, 2 also had inflammatory arthritis and one
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Table 2.1. Demographic, serological and clinical characteristics of RA patients
RA Patients (n=137)
Demographic Features
No. (%) Female
Age, median (range) years
Disease duration, median (range) years
IgG anti-CCP2
No. positive (%)
Mean concentration, (range) (Units/mL)
Rheumatoid Factor
No. positive (%)
Smoking Historya
No. (%) with smoking history
Joint Symptomsb
No. (%) with joint swelling
Average No. of swollen joints

a
b

100 (73)
59 (19-82)
4 (0.17-51)
87 (64)
121.3 (6.0-475.0)
83 (61)
81 (61)
57 (47)
7.2

Data available for 132 RA patients
Data available for 121 RA patients; Joint swelling was determined by the treating
rheumatologist and was associated with active RA disease activity
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had secondary Sjögren’s syndrome. PsA patient sera were collected from SJHC (n=10)
or were provided by Dr. Dafna Gladman from the Centre for Prognosis Studies in the
Rheumatic Diseases, Toronto Western Hospital (n=27), all of whom either met CASPAR
criteria for PsA (22) or were diagnosed as having PsA by a rheumatologist in a
specialized PsA clinic. PsA patients were 46% female with a mean age of 53 years
(range 36-82).

This study was approved by the Human Ethics Committee of The

University of Western Ontario (London, ON, Canada) according to the Declaration of
Helsinki (REB #09684E and #100868).

2.2.2

Antigens

The following peptide antigens were used for antibody assays: i) JED, referred to here as
CitJED, a proprietary synthetic, cyclic peptide, 18 amino acids in length with 9 residues
of citrulline (5,23,24); and ii) Homocitrullinated JED (HomoCitJED), identical to CitJED
except that all 9 citrulline residues were replaced with homocitrulline. The sequences of
both peptides were confirmed by mass spectrometry and the purity was greater than 85%,
as provided by the supplier.
CitJED and HomoCitJED were synthesized by Creative Peptides (Shirley, NY, USA).
CitJED and HomoCitJED were dissolved in 15% HCl in sterile distilled water for direct
Enzyme-Linked

Immunosorbent

Assay

(ELISA)

and

for

inhibition

ELISAs.

HomoCitJED was dissolved in 15% HCl in sterile distilled water to increase its solubility.
Although water soluble, CitJED was also dissolved in 15% HCl in order to compare the
antibody-binding properties of CitJED and HomoCitJED. This treatment did not alter
peptide structure as determined by mass spectrometry and ELISA (data available upon
request).

2.2.3

Antibody assays

Human sera were tested for expression of IgG anti-CitJED and IgG anti-HomoCitJED
using direct antibody-binding ELISA. The protocol was adapted from Hill et al (4).
Wells of ELISA plates (Nunc Maxisorp, VWR) were coated overnight at 4˚C with 2 μg
of peptide (20 μg/mL; CitJED or HomoCitJED) per well in carbonate coating buffer, pH
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9.6. The wells were washed with wash buffer (PBS, 0.05% Tween) and blocked for 30
minutes at room temperature (RT) with 200 μl of blocking buffer (PBS, 0.1% BSA).
Serum samples were diluted 1:100 or higher in diluent (PBS, 0.1% BSA, 0.05% Tween).
100 μl of diluted sera were added to duplicate wells and incubated for 30 minutes at RT.
After washing, 100 μl of biotin-conjugated goat anti-human IgG (1:8000; Sigma) and
streptavidin horseradish peroxidase polymer (1:4000; Abcam) were added for 30 minutes
at RT. After washing again, 100 μl of 3,3’,5,5’-Tetramethylbenzidine substrate (Sigma)
was added to the wells and incubated for 10 minutes at RT. The reaction was stopped
with 50 μl of 1M H2SO4 and the absorbance was determined at 450 nm.
Anti-CitJED and anti-HomoCitJED antibody concentrations in tested serum samples
were determined by comparison to a reference serum sample, which was positive for both
antibodies. These concentrations were quantified in Arbitrary Units/mL (AU/mL). The
cut-off values for positive anti-CitJED and anti-HomoCitJED expression were 3.8
AU/mL and 25.3 AU/mL respectively. The cut-off values represent the mean antibody
concentration of healthy subjects + 2 standard deviations.

Anti-CitJED and anti-

HomoCitJED concentrations are reported as an average of at least 3 repeat determinations
(<20% inter-assay variation). The number of patients with antibody levels greater than
twice the upper limit of normal were also reported, similar to ACR criteria (20). IgG
anti-CCP2 and IgM Rheumatoid Factor (RF) concentrations were determined by
Pathology and Laboratory Medicine, London Health Sciences Centre (London, ON,
Canada) or by our laboratory using anti-CCP2 (Euroimmun) or RF (Inova Diagnostics)
ELISA kits.
Cross-reactivity of anti-CitJED and anti-HomoCitJED was determined by inhibition
ELISA. The protocol was adapted from Scinocca et al (5). Various amounts of soluble
peptide in diluent were incubated with diluted RA patient sera for 1 hour at RT prior to
addition to ELISA wells coated with CitJED or HomoCitJED and carried out as
described for direct antibody-binding ELISA. Inhibition assays were repeated at least 2
times for each patient. Sera were selected for inhibition ELISA based on antibody
concentration which were a minimum of 10 AU/mL for anti-CitJED and 70 AU/mL for
anti-HomoCitJED.

These minimum concentrations were required to obtain a dose-
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dependent, reproducible inhibition. Anti-CitJED and anti-HomoCitJED were considered
as cross-reactive if inhibition with the non-cognate peptide was equal or higher than 50%
at any inhibiting peptide concentration.

2.2.4

Statistical analysis

Graphpad Prism 6.0 software was used for data analysis. Fisher’s exact test was used for
comparison of categorical values.

The Kruskal-Wallis Test with Dunn’s multiple

comparison was used to compare expression of anti-CitJED and anti-HomoCitJED in
RA patients to healthy subjects, SLE patients, and PsA patients (p<0.005 was considered
significant). Correlation between anti-CitJED and anti-HomoCitJED expression was
tested using Spearman’s correlation. Two-way ANOVA with Bonferonni correction was
used for statistical analysis of inhibition experiments (p<0.01 was considered significant).

2.3 Results
2.3.1

Occurrence of anti-CitJED and anti-HomoCitJED antibodies
in RA patients, healthy subjects and patients with SLE or
PsA

IgG antibodies reactive to CitJED and HomoCitJED were assessed in 137 RA patients,
51 healthy subjects, 37 SLE patients, and 37 PsA patients. Anti-CitJED levels were
significantly higher in RA patients compared to other groups (p<0.0001; Figure 2.1A).
Anti-CitJED was expressed in 69/137 (50%) of RA patients; 54/69 (78%) of these RA
patients had anti-CitJED levels greater than twice the cut-off. Anti-CitJED was detected
in 2/51 (4%) of healthy subjects, and was not detected in patients with SLE or PsA. AntiHomoCitJED was also detected at elevated levels in RA patients compared to other
groups (p<0.0001; Figure 2.1B). Of the RA patients, 78/137 (57%) were positive for
serum anti-HomoCitJED with 49/78 (63%) of these anti-HomoCitJED positive RA
patients having antibody levels greater than twice the cut-off.

In contrast, only 4/51

(8%) of healthy subjects had low levels of anti-HomoCitJED. Anti-HomoCitJED was
not found in PsA, but was detected in 1 patient with SLE with a concentration of 162.6
AU/mL. This SLE patient was felt to have an overlap connective tissue disease with
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Figure 2.1. Serum anti-CitJED and anti-HomoCitJED levels are increased in RA patients. Serum anti-CitJED (A) and antiHomoCitJED (B) were screened in RA patients (n=137), healthy subjects (n=51), SLE patients (n=37) and PsA patients (n=37). Cutoff values were 3.8 AU/mL for anti-CitJED and 25.3 AU/mL for anti-HomoCitJED. Grey bars represent the median concentration.
Number and percentages of positive sera, median concentrations and the interquartile range are shown below the respective group.
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features of both SLE and RA given that this patient had erosive inflammatory arthritis
and was also anti-CCP2 positive. These results indicate that anti-CitJED and antiHomoCitJED antibodies are frequently present at high concentrations in RA patients, and
infrequently found in healthy subjects, SLE or PsA patients.

2.3.2

Co-expression of anti-CitJED and anti-HomoCitJED
antibodies in RA patients

Forty-eight of 137 (35%) RA patients were negative for both anti-CitJED and antiHomoCitJED, while 58/137 (42%) of RA patients were positive for both antibodies.
Eleven of 137 (8%) and 20/137 (15%) of RA patients were single positive for antiCitJED or anti-HomoCitJED, respectively. Thus, anti-CitJED and anti-HomoCitJED
have a concordance of 77%. A strong correlation was found in the levels of serum antiCitJED and anti-HomoCitJED (Spearman rs=0.6676, p<0.0001; Figure 2.2) and we
observed an association between anti-CitJED and anti-HomoCitJED antibody expression
with an odds ratio of 12.65 (95% CI: 5.52-29.00). The levels of anti-HomoCitJED in
patients with anti-CitJED and anti-HomoCitJED were significantly greater compared to
patients who had anti-HomoCitJED alone (p<0.001, data not shown).
The expression of anti-CitJED and anti-HomoCitJED in relation to anti-CCP2 is shown
in Figure 2.3. Eighty-seven of 137 (64%) RA patients were positive for anti-CCP2. Of
the anti-CCP2 positive RA patients, 53/87 (61%) expressed anti-CitJED and 58/87 (67%)
were positive for anti-HomoCitJED. In the 50 RA patients who lacked anti-CCP2, 16/50
(32%) had anti-CitJED and 20/50 (40%) had anti-HomoCitJED. Only 6/137 (4%) of RA
patients were positive for anti-HomoCitJED and negative for both anti-CitJED and antiCCP2; Only 1 of these patients had anti-HomoCitJED levels greater than twice the cutoff. Thirty-six of 137 (26%) RA patients were negative for both anti-CCP2 and/or RF.
In this latter subpopulation, 12/36 (33%) of RA patients expressed anti-CitJED and/or
anti-HomoCitJED; 2/36 (6%) only expressed anti-CitJED, 2/36 (6%) only expressed antiHomoCitJED and 8 expressed both antibodies).
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Figure 2.2. Serum anti-CitJED and anti-HomoCitJED levels are correlated in RA.
Correlation graph comparing serum anti-CitJED and anti-HomoCitJED concentrations of
RA patients (n=137). The levels of IgG anti-CitJED and anti-HomoCitJED antibodies
were compared by Spearman nonparametric correlation.
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Figure 2.3. Anti-CitJED and anti-HomoCitJED are found in anti-CCP2 positive and anti-CCP2 negative RA patients.
Frequency and percentage of anti-CitJED and anti-HomoCitJED subpopulations in anti-CCP2 positive RA patients (A) and anti-CCP2
negative RA patients (B).
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2.3.3

Cross-reactivity of anti-CitJED and anti-HomoCitJED
antibodies

To examine the cross-reactivity of anti-CitJED and anti-HomoCitJED, we performed
inhibition ELISAs on RA sera (Figure 2.4) which met required anti-CitJED levels of 10
AU/mL and/or anti-HomoCitJED levels of 70 AU/mL as described in Materials and
methods. We examined 15 anti-CCP2 positive and 2 anti-CCP2 negative RA patients
that expressed both anti-CitJED and anti-HomoCitJED (referred to here as double
positive) (Figure 2.4A, Figure 2.4B, Appendix 1, and Appendix 2) We also examined 5
patients that were anti-CitJED positive but anti-HomoCitJED negative (anti-CitJED
single positive) (Figure 2.4C and Appendix 3) and 5 patients who were anti-HomoCitJED
positive but anti-CitJED negative (anti-HomoCitJED single positive) (Figure 2.4D and
Appendix 3). These single positive patients were also positive for anti-CCP2. None of
the sera from single positive patients who were anti-CCP2 negative met the required
antibody concentrations for the inhibition assay.
Anti-CitJED and anti-HomoCitJED from double positive and single positive RA patients
were inhibited by both CitJED and HomoCitJED peptides (Figure 2.4). The binding
affinity for CitJED and HomoCitJED peptides was examined by comparing the peptide
concentrations of CitJED and HomoCitJED required to achieve 50% inhibition of
antibody reactivity. The cognate peptide produced significantly greater inhibition of
antibody reactivity (p<0.0001; Figure 2.4). In double positive and anti-CitJED single
positive RA patients, inhibition exceeding 50% of anti-CitJED binding activity required 2
μg/mL of CitJED on average, compared to 100 μg/mL for HomoCitJED (Figure 2.4A and
Figure 2.4C). Anti-CitJED from 2/5 anti-CitJED single positive patients showed little to
no inhibition by HomoCitJED (Appendix 3). In double positive RA patients, inhibition
of 50% of anti-HomoCitJED binding activity required 10 μg/mL of HomoCitJED
compared to 50 μg/mL for CitJED (Figure 2.4B). In the group of anti-HomoCitJED
single positive patients, 50% inhibition of anti-HomoCitJED activity required 50 μg/mL
of HomoCitJED compared to 100 μg/mL of CitJED (Figure 2.4D). These results indicate
that anti-CitJED and anti-HomoCitJED antibodies are cross-reactive, and have a higher
inferred binding affinity to their respective cognate peptide.
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Figure 2.4. Anti-CitJED and anti-HomoCitJED from anti-CCP2 positive and anti-CCP2 negative RA patients are crossreactive. Average inhibitions of anti-CitJED (A) and anti-HomoCitJED (B) from 15 anti-CCP2 positive and 2 anti-CCP2 negative
RA patients who were positive for both anti-CitJED and anti-HomoCitJED. Average inhibitions of anti-CitJED from 5 anti-CitJED
single-positive RA patients (C) and average inhibitions of anti-HomoCitJED from 5 anti-HomoCitJED single-positive RA patients
(D). Anti-CitJED and anti-HomoCitJED single-positive RA patients had anti-CCP2. ELISA plates were coated with 20 μg/mL
(2ug/well) of CitJED (A,C) or HomoCitJED (B,D). p<0.01 was considered significant by Two-way ANOVA.
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2.4 Discussion
In this study, we used synthetic citrullinated and homocitrullinated peptides, containing
equal numbers of citrulline or homocitrulline residues, to examine the expression pattern
and cross-reactivity of ACPA (represented by anti-CitJED) and AHCPA (represented by
anti-HomoCitJED) in RA patients. We found that antibodies reactive to CitJED, and
HomoCitJED, were frequently expressed in the serum of RA patients. These antibodies
were rarely found in healthy individuals and in patients with SLE or PsA. The expression
of anti-CitJED and anti-HomoCitJED antibodies was 77% concordant. Additionally, we
have demonstrated that anti-CitJED and anti-HomoCitJED are frequently cross-reactive
in the patients studied and have higher affinity for the cognate peptide.
We detected IgG anti-HomoCitJED antibodies in 57% of RA patients, a higher
proportion than what was reported for other antibodies targeting homocitrullinated
proteins or peptides (19-45%) (8,17–19,25–27). Similarly, IgG anti-HomoCitJED was
expressed in a significant proportion (28%) of anti-CCP2/RF negative RA patients.
Antibodies to homocitrullinated proteins and peptides have been previously reported in
anti-CCP2-negative RA patients to varying degrees (8,18,25–27). This variability may
be attributed to several factors, including differences in the characteristics of the study
populations (genetics, environmental exposures and disease activity). Consistent with a
prior study, we did not observe a significant difference in IgG anti-HomoCitJED
expression between RA patients with and without a history of smoking (data not shown)
(25). Our RA population had longer disease duration compared to the other studies and
therefore may have developed more AHCPA reactivity over time. We have also found
that IgG anti-HomoCitJED were rarely found in healthy individuals and patients with
SLE or PsA.

The specificity of IgG anti-HomoCitJED for RA requires further study

with other types of inflammatory conditions. Some studies have identified antibodies to
carbamylated fetal calf serum (anti-CarP-FCS) in other inflammatory arthritides and
connective tissue diseases (in up to 50% of patients) (26–30).
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Prior studies did not examine the extent and affinity of antibody cross-reactivity of
antibodies to citrullinated or homocitrullinated peptides, leading to the question of
whether ACPA and AHCPA are part of a single antibody family or 2 separate antibody
systems. We performed detailed inhibition experiments, allowing for analyses of the
prevalence and affinity of cross-reactive ACPA and AHCPA.

Using CitJED and

HomoCitJED peptides which have equal numbers of citrulline and homocitrulline
residues respectively, we observed that anti-CitJED and anti-HomoCitJED antibodies
were inhibited by both peptides in the majority of RA patients (25/27 of RA patients
examined by inhibition ELISA), including those who were positive for only one of these
antibodies by direct ELISA.

The difference in antibody peptide-binding activity

observed between direct ELISA and inhibition ELISA could be caused by lower peptide
concentrations used in direct ELISA, or possibly due to conformational differences
between soluble peptides and plate-bound peptides. These results suggest significant
cross-reactivity between ACPA and AHCPA and support the notion that these antibodies
are part of the same antibody family, as proposed by Reed et al (19). Cross-reactivity to
citrullinated and homocitrullinated antigens has also been demonstrated in experimental
animals. Turunen et al. showed that immunization with homocitrullinated antigens led to
the development of anti-citrulline reactivity in rabbits (15). Furthermore, Mydel et al.
observed the development of erosive arthritis in mice, immunized with a
homocitrullinated filaggrin peptide followed by the introduction of citrullinated filaggrin
peptide into the knee (31).
In RA, it is not known whether citrullinated or homocitrullinated antigens (or both) are
responsible for the initiation of autoantibody development. ACPA and AHCPA have
been detected in patients years prior to disease onset (6,10,11,32). Furthermore, the anticitrullinated protein antibody response has been demonstrated to undergo epitope
spreading, resulting in an expansion of the ACPA repertoire over time (32). Because of
the structural similarity between citrulline and homocitrulline, epitope spreading may
lead to ACPA acquiring AHCPA specificities or vice versa. We observed that the degree
of cross-reactivity varied between RA patients with the majority having higher affinity
for the cognate antigen. This finding likely reflects the abundance of the cognate antigen,
which drives B cell maturation towards the production of higher affinity antibodies to the
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same antigen. We identified 2 patients that did not have cross-reactive antibodies who
were both anti-CitJED positive, however, we did not determine whether these patients
would later develop cross-reactivity to homocitrulline.
There are limitations to this study: measurements were performed at one time point, few
patients had early disease and samples from pre-RA subjects were not available. Future
longitudinal studies of early and pre-RA patients could provide a better understanding of
the role of anti-homocitrulline and anti-citrulline antibodies in the initiation and
progression of RA. Detailed clinical information was also not available; therefore, we
could not assess the impact of the cross-reactivity and affinity of these antibodies on RA
disease activity and severity.
In conclusion, antibodies to HomoCitJED and CitJED were frequently found in RA
patients and were rare in other conditions. These findings demonstrate the immunologic
relatedness of ACPA and AHCPA as detected by assays using CitJED and HomoCitJED
peptides with equal numbers of citrulline and homocitrulline residues, and suggest that
these antibodies are potentially derived from the same B cell population. Cross-reactive
B cells may provide a mechanism by which AHCPA are involved in RA pathogenesis.
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Chapter 3

3

Immune responses to peptides containing
homocitrulline or citrulline in the DR4-transgenic mouse
model of rheumatoid arthritis

This chapter has been prepared for submission to The Journal of Autoimmunity.

3.1 Introduction
RA is characterized by the production of autoantibodies that target citrullinated
proteins/peptides (ACPA). Clinically, the most commonly measured ACPA is anti-cyclic
citrullinated peptide antibodies (anti-CCP2), which are highly specific for RA (1,2) and
predictive of erosive joint disease (3,4). The susceptibility to ACPA-positive RA is
significantly higher in individuals expressing HLA alleles (5,6) that encode a consensus
sequence called the Shared Epitope (SE) (7). The SE binds to peptides containing
citrulline with high affinity initiating citrulline-specific T and B cell responses (8,9).
Target antigens for these immune responses are present in the joint, including
citrullinated fibrinogen (10), α-enolase (11,12), vimentin (13,14) and collagen II (15).
Evidence suggests that ACPA bind to these targets in the joint leading to complement
activation and chronic inflammation (16). Experiments done in animal models further
support the notion that T and B cell citrulline-specific immune responses are pathogenic
(17–20).
It is known that some ACPA also bind peptides or proteins containing homocitrulline
(21–24), an amino acid that is structurally related to citrulline and is also present in RA
synovium (25,26). Antibodies to homocitrullinated antigens (also referred to as anticarbamylated antibodies (anti-CarP)) have been detected in the sera of RA patients
(21,27–30) and are associated with more severe disease (27,31). In silico evidence
suggests that homocitrullinated peptides can be accommodated within the binding groove
of the SE (21). However, the relationship between the SE and homocitrullinated peptides
remains unclear. When immunized with homocitrullinated filaggrin-derived peptides and
given an intra-articular injection of citrullinated peptide, different strains of mice
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developed arthritis with varying frequency, suggesting that the MHC-H2 haplotype
influences the development of arthritis (32). The objective of this study was to examine
the role of the SE in the development of immune responses to a peptide containing
homocitrulline using a humanized SE-expressing DR4-transgenic mouse model of RA.

3.2 Materials and methods
3.2.1

Antigens

The antigens used in this study were Citrullinated JED (CitJED) (21,33,34) and
Homocitrullinated JED (HomoCitJED), which are synthetic cyclic peptides containing
18 amino acids with 9 residues of citrulline and homocitrulline, respectively. These
peptides were synthesized by Creative Peptides (Shirley, NY, USA). Human fibrinogen
(VWR) was left unmodified or was citrullinated or homocitrullinated for the antibody
assays. Citrullination of fibrinogen was previously described by Hill et al (35) and
homocitrullination was performed as per the method of Scinocca et al (21).

3.2.2

Mice and immunizations

DR4-IE transgenic mice deficient in endogenous MHC class II on the C57Bl/6
background (referred to as DR4tg) (17,36) were bred in house. C57Bl/6 mice (B6) mice
were purchased from The Jackson Laboratory (Maine, USA). Both strains of mice were
housed in pathogen-free conditions at the Animal Care and Veterinary Services barrier
facility at the University of Western Ontario as per the Canadian Council on Animal Care
guidelines. The study was approved by the Animal Care and Use Committee (The
University of Western Ontario, London ON, Canada). Female and male DR4tg and B6
mice were immunized and boosted 21 days later with 100 μg of HomoCitJED suspended
in PBS or PBS alone using the method of Hill et al (17).

3.2.3

Splenocyte proliferation

The splenocyte proliferation assay was adopted from Hill et al (17). In brief, splenocytes
were harvested from mice sacrificed at various time points and cultured in complete
RPMI media (Gibco) at a concentration of 4 x 105 splenocytes/well. Splenocytes were
treated with 100 μg/mL of CitJED, HomoCitJED, or no peptide and incubated for 54
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hours at 37°C, 5% CO2. One μCi of 3H-thymidine was added to each well and incubated
for an additional 18 hours. Splenocytes were harvested using a Harvester96 (Tomtec)
and radioactivity was measured with a MicroBeta JET (Perkin Elmer). Proliferation
experiments were conducted at least in quadruplicate and replicate counts per minute
(cpm) were averaged (<20% intra-assay variation). Proliferative responses are reported
as a Stimulation Index (SI; cpm of samples with peptide/cpm of samples with media
alone) +/- standard error of the mean. A cut-off value of 2.0 was considered a positive
proliferative response.

3.2.4

Antibody assays

Sera from mice at various time points were screened for IgG anti-HomoCitJED, antiCitJED, anti-citrullinated fibrinogen (anti-CitFib), anti-homocitrullinated fibrinogen
(anti-HomoCitFib), anti-fibrinogen (anti-Fib) and anti-cyclic citrullinated peptide (antiCCP2) antibodies by direct antibody-binding ELISA. HomoCitJED and CitJED were
dissolved in 15% HCl in sterile distilled water. The 15% HCl did not alter the structure
of CitJED or its binding properties (data available upon request). The protocol for antiHomoCitJED and anti-CitJED direct antibody-binding ELISA was similar to Hill et al
(35) with the following modifications: wells were coated with 20 μg/mL of HomoCitJED
or 40 μg/mL of CitJED in carbonate coating buffer, and 100 μL/well of biotin-conjugated
goat anti-mouse IgG (1:5000; Jackson) with streptavidin horseradish peroxidase polymer
(1:4000; Abcam) were used for antibody detection. The ELISA protocol for anti-CitFib,
anti-HomoCitFib and anti-Fib was also adapted from Hill et al (35) as described above,
but 10 μg/mL of CitFib, HomoCitFib and Fib in carbonate coating buffer were used
instead of the peptides. These ELISAs were performed twice for each serum sample and
the average OD was reported (<20% inter-assay variation). The detection of anti-CCP2
antibodies in mouse sera was performed using an anti-CCP2 ELISA kit (Euroimmun).
The manufacturer’s protocol was followed with the exception that peroxidase-conjugated
rabbit anti-mouse IgG (1:5000, Dako) was used. The optical density was determined at
450 nm. The cut-off value for anti-CCP2 was 0.38 OD equal to two standard deviations
above the mean value for PBS-immunized B6 mice. The cut-off values for the other
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antibodies were 0.1 OD, which is the lower detection limit of the ELISA (the mean
values for these antibodies in PBS immunized mice were below 0.1).
The cross-reactivity of IgG anti-HomoCitJED, anti-CitJED, and anti-CCP2 antibodies
was examined by inhibition ELISA. The protocol was adapted from Scinocca et al (21)
with the following plate-bound antigens: CitJED, HomoCitJED and CCP2. Inhibitions
were performed with soluble CitJED and HomoCitJED at various concentrations (2 to
100 μg/mL). The average percent inhibition of two repeat determinations is reported,
except for CCP2 that was performed once due to insufficient quantity of sera.

A

minimum OD of 0.5 by direct antibody-binding ELISA was required to obtain a dosedependent, reproducible inhibition.

3.2.5

Statistical analysis

Graphpad Prism 6.0 software was used for data analysis. The Mann-Whitney U test was
used to compare SI or OD between DR4tg and B6 mice at the indicated time points
(p<0.05 was considered significant). Two-way ANOVA with Bonferonni correction was
used for statistical analysis of inhibition experiments (p<0.01 was considered significant).

3.3 Results
3.3.1

Splenic T cell proliferative responses

Splenocytes from DR4tg and B6 mice were assessed for proliferative responses to
HomoCitJED and CitJED peptide by 3H-thymidine incorporation assay. In DR4tg mice,
HomoCitJED-specific splenocyte proliferative responses were observed as early as day
10 in 3/7 (43%) of mice post-immunization with HomoCitJED.

These responses

increased at later time points with 9/11 (82%) of mice having a significant proliferative
response to HomoCitJED at day 100 (Figure 3.1A). We also monitored DR4tg mice for
T cell proliferative responses to CitJED peptide (Figure 3.1B). Proliferation to CitJED
was observed mainly in mice at day 100, with splenocytes from 8/9 (89%) of mice
proliferating in response to CitJED stimulation. In DR4tg mice immunized with PBS,
HomoCitJED-specific T cell proliferation was not detected, but CitJED-specific T cell
proliferation was detected in 2/9 (22%) at 100 days; the proliferative responses to CitJED
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Figure 3.1. Splenocyte proliferative responses in DR4tg () and B6 () mice.
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were significantly lower in PBS-immunized DR4tg mice compared to HomoCitJEDimmunized DR4tg mice (p<0.05; data not shown).
To determine whether T cell responses to HomoCitJED and CitJED were restricted to
SE-expressing DR4tg mice, we also examined the splenocyte proliferative response in B6
mice which lack the SE. HomoCitJED-immunized B6 mice developed HomoCitJEDspecific T cell responses, however these appeared only at day 100 in 4/9 (44%) of mice
(Figure 3.1A). These mice did not have CitJED specific T cell responses (Figure 3.1B).
Splenocytes from PBS-immunized B6 mice did not proliferate to either peptide (data not
shown).

3.3.2

Antibodies to citrulline- and homocitrulline-containing
antigens in DR4tg and B6 mice

Sera from DR4tg and B6 mice were screened for the presence of various antibodies
targeting citrullinated and homocitrullinated proteins or peptides (Figure 3.2). In DR4tg
mice immunized with HomoCitJED, anti-HomoCitJED antibodies were detected in a
small proportion (6/22, 27%) of mice at day 10 post-immunization, followed by an
increase in anti-HomoCitJED antibody expression at subsequent time points (Figure
3.2A). The peak of anti-HomoCitJED activity occurred at day 70, at which time 11/11
(100%) of DR4tg mice were positive for these antibodies. The expression of antiHomoCitFib antibodies (Figure 3.2B) also occurred in a similar pattern over time (the
concordance of anti-HomoCitJED and anti-HomoCitFib antibodies was 86%).
Antibodies to citrullinated peptides were present at later time points (day 50 and 70 postimmunization) with 7/11 (64%) of mice expressing anti-CitJED and 8/11 (73%)
expressing anti-CCP2 antibodies at day 70 (Figure 3.2C and Figure 3.2D). Moreover,
anti-CitJED and anti-CCP2 were concordantly expressed in 88% of DR4tg mice. There
were no detectable antibodies to CitFib and only 1 mouse had a low antibody response to
Fib (data not shown). All DR4tg mice that had antibodies targeting citrullinated peptides
also expressed anti-HomoCitJED antibodies.
In B6 mice immunized with HomoCitJED, antibody responses to HomoCitJED and
HomoCitFib were observed at a later time point compared to DR4tg (day 100) in 4/9
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Figure 3.2. Antibody responses in DR4tg () and B6 () mice. Sera from HomoCitJED-immunized mice were screened for the
presence of anti-HomoCitJED (A), anti-homocitrullinated fibrinogen (B), anti-CitJED (C), and anti-CCP2 (D) antibodies at the time
points indicated post-immunization. Antibody levels, determined by direct ELISA, are shown as the mean optical density (± the
SEM). Optical densities above the cut-off value are indicated by the dashed line. The cut-off values were 0.38 for anti-CCP2 and 0.1
for the other antibodies. * - p<0.05, ** - p<0.01, *** - p<0.001, **** - p<0.0001 by the Mann-Whitney U test. Each symbol
represents one mouse; n=6-22.
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(44%) and 2/9 (22%) mice, respectively (concordance = 71%; Figure 3.2A and Figure
3.2B). These B6 mice did not respond to citrullinated antigens except for one mouse that
had a low response (Figure 3.2D). PBS-immunized B6 or DR4tg mice did not have
significant antibody responses to any of the antigens tested (data not shown).

3.3.3

Antibody cross-reactivity in DR4tg and B6 mice

To examine anti-CitJED and anti-HomoCitJED antibody cross-reactivity, antibodies from
DR4tg mouse sera were inhibited with soluble CitJED and HomoCitJED peptides. We
inhibited IgG anti-HomoCitJED from 8 DR4tg mice that had anti-HomoCitJED
antibodies, but lacked anti-CitJED based on direct ELISA (Figure 3.3A). In these mice,
anti-HomoCitJED antibodies were efficiently inhibited by cognate HomoCitJED peptide.
However, two patterns emerged when these antibodies were inhibited with CitJED
(Appendix 4). In 5/8 mice, anti-HomoCitJED were not inhibited by CitJED, which
suggests that these antibodies were HomoCitJED-specific. In the other 3 mice, antibody
reactivity to HomoCitJED was significantly inhibited by CitJED peptide, indicating that
anti-HomoCitJED antibodies in these mice were cross-reactive. Antibodies from serum
collected at various time points (days 10-70 post-immunization) were tested in the
inhibition assays; antibody cross-reactivity did not appear to be influenced by the time at
which it was measured (Appendix 4).
In DR4tg mice that expressed both anti-HomoCitJED and anti-CitJED antibodies by
direct ELISA, anti-HomoCitJED antibodies were inhibited by HomoCitJED, but were not
inhibited by CitJED (Figure 3.3B and Appendix 5A-C).

However, anti-CitJED

antibodies from the same three mice were inhibited by both HomoCitJED and CitJED
peptide (Figure 3.3C and Appendix 5D-F). Anti-CitJED in these mice was inhibited
more efficiently by the non-cognate peptide, HomoCitJED (p<0.0001).
We also examined the antigen specificity of anti-CCP2 antibodies in DR4tg mice (Figure
3.4). Similar to anti-CitJED, anti-CCP2 antibodies were always co-expressed with antiHomoCitJED in DR4tg mice (n=4). Anti-CCP2 antibodies from 3/4 mice were efficiently
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Figure 3.3. Inhibition of anti-HomoCitJED (black bars) and anti-CitJED (grey bars) antibodies. Sera from HomoCitJEDimmunized DR4tg mice were used in inhibitions assays. As measured by direct ELISA, these mice expressed anti-HomoCitJED
antibodies but not anti-CitJED antibodies (n=8; A) or were positive for both anti-HomoCitJED and anti-CitJED antibodies (n=3; B,
C). The mean percent inhibition (pooled from inhibitions performed on n=3 or 8 mice) ± the SEM is shown. * - p<0.0001 by Twoway ANOVA with Bonferonni correction.
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Figure 3.4. Inhibition of anti-CCP2 antibodies. Sera from four HomoCitJED-immunized DR4tg mice (DR4tg #12-15; A-D) were
used in inhibition assays at the indicated days post-immunization. As detected by direct ELISA, these mice expressed anti-CCP2
antibodies. The percent inhibition from one experiment per individual mouse serum is shown.
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inhibited by HomoCitJED peptide (Figure 3.4 A-C). Two of these mice had anti-CCP2
antibodies that were also inhibited by CitJED (Figure 3.4A and Figure 3.4B). In one
mouse, anti-CCP2 antibodies were not efficiently inhibited by either CitJED or
HomoCitJED (Figure 3.4D).
To determine whether antibody cross-reactivity was affected by the SE, we also inhibited
anti-HomoCitJED from four B6 mice (Figure 3.5).

By direct ELISA, these mice

expressed anti-HomoCitJED, but were negative for anti-CitJED and anti-CCP2
antibodies. In these mice, anti-HomoCitJED antibodies were inhibited by HomoCitJED
peptide; there was no difference in the relative affinity of anti-HomoCitJED antibodies
for HomoCitJED in B6 compared to DR4tg mice (Appendix 6).

However, anti-

HomocitJED antibodies from B6 mice were not inhibited by CitJED peptide. Thus,
unlike antibodies from DR4tg mice, anti-HomoCitJED antibodies from B6 mice were not
cross-reactive.

3.4 Discussion
In this study, we immunized DR4tg and B6 mice with a synthetic homocitrullinated
peptide, HomoCitJED and examined the development of splenic T cell proliferative and
antibody responses to homocitrullinated and citrullinated peptides and proteins.

In

DR4tg mice that expressed the SE and were immunized with HomoCitJED, we detected
the early development of splenocyte proliferative and antibody responses to
HomoCitJED. These mice also generated antibodies to HomoCitFib, an antigen shown to
be present in the RA synovium (26). Anti-HomoCitJED antibodies from DR4tg mice
also bound citrullinated antigens (CitJED and CCP2), supporting the notion that these
antibodies are cross-reactive.
It is known that there is a strong association between the SE and anti-citrullinated
protein/peptide antibodies (ACPA) in RA patients (5). Studies have shown that the SE
binds citrullinated peptides with high affinity, initiating T and subsequently B cell
responses (8,9).

In DR4tg mice, but not B6 mice, immunization with citrullinated

fibrinogen causes arthritis suggesting that the SE is necessary for arthritis development
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Figure 3.5. Inhibition of anti-HomoCitJED from B6 mice. Inhibition assays were performed on sera from four HomoCitJEDimmunized B6 mice (B6 #1-4; A-D) at day 100 post-immunization. As measured by direct ELISA, these mice expressed antiHomoCitJED antibodies but lacked both anti-CitJED and anti-CCP2 antibodies. The mean percent inhibition of 2 repeats per
individual mouse serum ± the SEM is shown. * - p<0.0001 by Two-way ANOVA with Bonferonni correction.
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(17,20). The chemical structure of homocitrulline is identical to citrulline except for one
carbon atom; however, the affinity of homocitrullinated peptides for the SE and its effect
on the immune response is unknown. Moreover, the association between the SE and antiCarP was not found in a study of RA patients from Northern Europe (29).

The

association between the SE and other anti-homocitrullinated protein/peptide antibodies
(AHCPA) in other populations has not been previously studied. Immune responses to
homocitrullinated antigens occur in mice expressing different MHC-H2 alleles (32). Our
study is the first to use mice that express the SE and not endogenous mouse MHC class II
molecules to study responses to homocitrulline and although we show that some B6 mice
that express MHC-H2b did develop responses to homocitrullinated antigens, the DR4tg
mice had earlier responses. It is possible that I-Ab from B6 mice binds homocitrulline
poorly. In contrast, DR4 may be able to bind homocitrulline with high affinity, similar to
citrulline (8,9), in its P4 binding pocket via the SE, accelerating T and B cell responses to
homocitrullinated peptides.
In addition to earlier T and B cell responses to homocitrullinated peptides and proteins,
DR4tg mice immunized with HomoCitJED had sustained responses from day 10 to 100
post-immunization.

Sustainability of an immune response may enhance epitope

spreading (37), which is supported by our finding that DR4tg mice developed responses
to citrullinated peptides and proteins at day 100 post-HomoCitJED immunization. The
ACPA responses from these mice had a higher inferred affinity by inhibition assays for
HomoCitJED than CitJED, suggesting that the ACPA arise from B cell responses to
HomoCitJED. As in other studies showing that AHCPA are cross-reactive (21–24), some
anti-HomoCitJED antibodies from DR4tg mice also bound CitJED. Notably, B6 mice
immunized with HomoCitJED did not develop antibodies to citrullinated antigens and
anti-HomoCitJED antibodies from these mice did not bind CitJED, providing further
evidence for the strong relationship between SE and citrullinated peptides.
Our study has several other strengths. We used a homocitrullinated peptide and its
citrullinated counterpart that had the same backbone sequence and identical location and
number of modified amino acids, minimizing the effect of the backbone on the
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assessment of the immune response. These synthetic peptides can act us surrogate
antigens for an endogenously expressed modified protein (fibrinogen), known to be
involved in the pathogenesis of RA (10,17,21,38). The animal model we used is relevant
to human RA in that the mice express the strongest genetic risk factor for this disease
(39). We describe the immune responses in these mice over an extended period of time.
Detailed inhibition analyses were performed to examine the relative affinity of the antiHomoCitJED and anti-CitJED antibodies from these mice.

Unfortunately, we were

unable to perform more extensive inhibition with other antigens due to insufficient sera
volume. Another limitation is that we did not continue our experiments past day 100
post-immunization at which time the DR4tg mice immune responses started to decline,
while in B6 mice, they were first detected.
In conclusion, this study revealed that HomoCitJED is immunogenic leading to T and B
cell responses to homocitrullinated antigens in SE-expressing DR4tg mice, which later
evolve into immune responses to citrullinated antigens. This evolution appears to be
driven by epitope spreading rather than de novo generation of citrullinated antigens and
relies on the SE. These mice did not develop arthritis, however, in other animal models,
arthritic mice expressed antibodies to homocitrullinated antigens (40). Future work will
assess the arthritogenic properties of anti-homocitrulline immune responses in the DR4tg
mouse model.
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Chapter 4

4

Discussion

4.1 Summary
In this study, the objectives were to investigate the anti-homocitrulline as well as the anticitrulline immune responses in RA patients and in a mouse model of RA (DR4tg and B6
mice). The major findings in chapter 2 were that anti-HomoCitJED and anti-CitJED
antibodies were frequently and specifically detected in RA patients.

These two

antibodies were co-expressed in RA patients and were cross-reactive. In chapter 3,
DR4tg and B6 mice were immunized with HomoCitJED and the immune responses to
HomoCitJED were examined. Anti-homocitrulline immune responses were shown for
the first time to be associated with the SE. These responses could also occur in the
absence of the SE but the development of cross-reactive anti-citrulline responses only
occurred in DR4tg mice.

4.2 Anti-homocitrulline antibodies are specifically
associated with RA and are cross-reactive to citrulline
Anti-homocitrulline antibodies are a family of antibodies that have been recently
associated with RA.

However, some aspects of these antibodies, including the

prevalence of these antibodies in RA patients, their specificity for disease, as well as their
relationship with anti-citrulline antibodies are not well understood. The studies that have
been performed thus far on anti-homocitrulline and anti-citrulline cross-reactivity are few
in number and have used different homocitrulline-containing antigens with limited
specificity (1–6).

Thus, a major strength of this study was the use of a novel,

homocitrulline-rich peptide (HomoCitJED) as a surrogate target of anti-homocitrulline
antibodies in RA patients (ie. designed with the potential to detect anti-homocitrulline
antibodies to numerous homocitrullinated antigens). CitJED, the citrulline-containing
counterpart of HomoCitJED, was used for the detection of anti-citrulline antibodies.
These peptides allowed for the examination of antibody reactivity (and cross-reactivity)
to homocitrulline and citrulline.
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The antibody responses to HomoCitJED and CitJED were evaluated for their specificity
for RA.

Another strength of this study design was the use of patients with other

inflammatory conditions as the most appropriate controls.

The presence of anti-

HomoCitJED and anti-CitJED antibodies was examined in sera from patients with PsA,
an inflammatory joint disorder that shares many clinical features with RA but are not
associated with autoantibody expression (7). Additionally, sera from patients with SLE,
an inflammatory autoimmune disorder that is associated with the development of
autoantibodies to DNA and ribonucleoproteins (8), were also screened for antibody
activity to HomoCitJED and CitJED.
Anti-CitJED antibodies were found to be specific for RA because they were not detected
in healthy subjects, SLE patients, nor PsA patients. This is in agreement with the
literature that other anti-citrulline antibodies to CCP (9–11), citrullinated fibrinogen (12)
and mutated citrullinated vimentin (13) are highly specific for RA. Previously, Reed et
al. suggested that anti-homocitrulline antibodies could be a biomarker of inflammation
instead of being specifically associated with RA (6). However, this was not the case for
anti-HomoCitJED as these antibodies were not detected in patients with other
inflammatory conditions (PsA or SLE).
Anti-HomoCitJED antibodies were detected in a large proportion of RA patients
(approximately 60%), and were found to be expressed alongside anti-CitJED in many of
these patients.

This is in agreement with the findings that the anti-CarP-FCS are

frequently found in anti-CCP positive RA patients (1,14). Anti-HomoCitJED and antiCitJED antibodies in patients that had both of these antibodies were inhibited by both
HomoCitJED and CitJED peptides (cross-reactive). In addition, a small proportion of
RA patients were positive for anti-HomoCitJED but not anti-CitJED (15%) or the
converse (8%) as measured by direct antibody ELISA. However, anti-HomoCitJED and
anti-CitJED from these patients were also inhibited by both HomoCitJED and CitJED.
Thus, the evidence presented here indicates that anti-homocitrulline and anti-citrulline
antibodies constitute a single, cross-reactive antibody population as proposed by Reed et
al (6).
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4.3 The SE is involved with anti-homocitrulline immune
responses and cross-reactivity to citrulline
This study examined the development of anti-homocitrulline and anti-citrulline immune
responses in DR4tg mice. This is a relevant model of RA because these mice express the
SE, which is found in the majority of RA patients (15–17) and confers disease
susceptibility (18).

DR4tg mice have also been shown to develop arthritis when

immunized with citrullinated fibrinogen (19), an antigen that has been found to be present
in the joints of arthritic DR4tg mice (19) as well as in the synovial tissue of RA patients
(20).
The T and B cell responses following immunization with HomoCitJED in mice with
(DR4tg mice) and without the SE (B6 mice) were investigated to examine i) the
development of anti-homocitrulline immune responses, ii) whether these immune
responses were SE-dependent, and iii) the cross-reactivity of anti-homocitrulline
responses to citrulline.
Anti-HomoCitJED T and B cell responses were observed in both DR4tg and B6 mice.
Additionally, antibodies to homocitrullinated fibrinogen could be detected in both mouse
strains and were found to be concordant with anti-HomoCitJED. The finding that antihomocitrulline responses can occur in the absence of the SE is in agreement with
previous work by Mydel et al. (21), and suggests that

homocitrulline can be

accommodated by some mouse MHC class II molecules, including I-Ab from B6 mice,
resulting in anti-homocitrulline immune responses. Nonetheless, this study provides the
first in vivo evidence that the immune response to homocitrulline is SE-associated.
A difference observed between DR4tg and B6 mice was that the immune responses in
DR4tg mice were more frequent and occurred earlier. This may indicate that SE-encoded
HLA-DR molecules are better binders of homocitrulline-containing peptides compared to
those without the SE. Thus, antigen presentation in DR4tg mice may be more efficient in
activating homocitrulline-specific T cells that help B cells to generate antibodies to this
peptide.
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The main difference between DR4tg mice and B6 mice was that immunization with
HomoCitJED also led to the development of T cell responses to CitJED and antibodies to
citrullinated peptides (CitJED and CCP) in (SE-positive) DR4tg mice. These immune
responses occurred later compared to the anti-homocitrulline immune responses in DR4tg
mice. Anti-citrulline antibodies were only found in mice that also had anti-HomoCitJED
and were also cross-reactive to HomoCitJED. This shows that the anti-homocitrulline
immune response precedes the anti-citrulline response in mice and the same may occur in
RA patients. In contrast, anti-citrulline T and B cell responses were not detected in (SEnegative) B6 mice in any of the assays used in this study. This reinforces the idea that
cross-reactivity between anti-homocitrulline and anti-citrulline immune responses is SEdependent.
The anti-homocitrulline and anti-citrulline antibody responses in DR4tg mice shared
similarities with the antibody responses that were observed in RA patients of this study.
DR4tg mice expressed antibodies to HomoCitJED, CitJED and CCP following
immunization with HomoCitJED, and similarly, these antibodies were also expressed by
RA patients. DR4tg mice developed anti-homocitrullinated fibrinogen antibodies, which
have also been reported to be present in the same cohort of RA patients as used here
(3,22). Antibodies in both the DR4tg mice and RA patients were cross-reactive. Not
surprisingly, due to the differences in genetic makeup, cross-reactivity was observed in a
different proportion of RA patients compared to DR4tg mice. These observations, in
addition to a previous study performed by the laboratory of Cairns and Bell (19), supports
the use of the DR4tg mouse model for the study of mechanisms underlying the
pathogenesis of RA.

4.4 Homocitrulline plays a role in RA pathogenesis
Autoimmunity involves the breakdown of immunological tolerance to self-tissues. In RA
patients, there is a loss of tolerance to citrullinated proteins as well as to
homocitrullinated proteins. This study provides evidence that homocitrulline is able to
induce both anti-homocitrulline and cross-reactive anti-citrulline immune responses.
This may be due to the structural similarity between homocitrulline and citrulline. The
combination of molecular mimicry, which exists when antigens share similar sequences
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(23,24), and B cell cross-reactivity to these related antigens (23) have previously been
described as driving factors in B cell epitope spreading.

Epitope spreading is the

diversification of epitopes that are recognized by the immune system (23) and has been
implicated in the development of autoimmune diseases including RA (23,25) and SLE
(23,26).
In RA, epitope spreading has been shown to cause an expansion in the repertoire of anticitrulline antibodies in patients prior to disease onset (25). The findings in this study
suggest that epitope spreading can also occur between the anti-homocitrulline and anticitrulline antibody responses and is dependent on the expression of the SE. Additionally,
B cells express MHC class II molecules and studies have shown that B cells are able to
activate antigen-specific T cells in mouse models of RA (27,28). Thus, cross-reactive B
cells with SE-encoded HLA-DR may be able to present homocitrulline- or citrullinecontaining epitopes to T cells. This could result in the propagation of immune responses
to both homocitrulline and citrulline in RA patients and further exacerbate the
autoimmune response in RA patients by promoting T cell activity.
Currently, the mechanism underlying RA pathogenesis is believed to involve the
presentation of citrullinated peptides by antigen presenting cells that express SE-encoded
HLA-DR molecules to citrulline-specific helper T cells, as initially described by Hill et al
(29). These T cells subsequently activate citrulline-specific B cells, which then drive the
production of anti-citrulline antibodies.

Evidence from this study suggests that

homocitrulline can play a similar role (Figure 4.1). Homocitrulline can be presented by
SE-encoded HLA-DR molecules and result in cross-reactive anti-homocitrulline and anticitrulline antibodies.

These cross-reactive antibodies can then bind to either

homocitrullinated or citrullinated antigens, which have been shown to be present in RA
joint tissue (21,30,31), resulting in inflammation and RA development.

Thus, it is

possible that homocitrulline plays a role in RA pathogenesis by contributing to the
breakdown of self-tolerance to citrulline and vice-versa.

However it is not known

whether homocitrulline or citrulline (or both) is responsible for RA development.
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Figure 4.1. Immune responses to homocitrulline in RA. Homocitrulline-containing
peptides are presented by SE-encoded HLA-DR on antigen presenting cells (APC)
resulting in T and B cell activation. Activated B cells produce cross-reactive antibodies
to homocitrulline and citrulline which mediate inflammatory responses in RA joint tissue.
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4.5 Limitations and future directions
This study examined the expression and cross-reactivity of anti-HomoCitJED and antiCitJED antibodies in RA patients with established (long-standing) disease. It is possible
that the longer disease durations allowed for the RA patients to develop more antihomocitrulline or anti-citrulline antibody activity over time (due to epitope spreading).
To better understand the development of the anti-homocitrulline and anti-citrulline
immune responses in RA patients, anti-HomoCitJED and anti-CitJED expression and
cross-reactivity will need to be studied in patients with early disease and in patients prior
to the onset of RA.
The studies in mice revealed that anti-homocitrulline antibodies can be generated in the
absence of the SE, but cross-reactivity to citrulline was dependent on the expression of
the SE. Whether this is the same in RA patients is unknown because the HLA haplotypes
of the RA patients were not investigated. Genotyping of RA patients will provide further
insight on the association of anti-homocitrulline and anti-citrulline responses with the SE.
Another limitation of this study was that the association between the SE and
homocitrulline was demonstrated using functional assays (T and B cell responses to
homocitrulline) in DR4tg mice. Further studies which examine whether homocitrullinecontaining peptides can directly bind to SE-encoded HLA-DR molecules are required to
confirm this finding.
Additionally, the mouse studies were limited by the duration of the study period. B6
mice were found to not develop cross-reactive immune responses to citrulline at any of
the time points examined. However, the immune responses in B6 mice were detected at
day 100 (the last day time point that was assessed). It is possible that the B6 mice would
later develop reactivity to citrulline. Thus, studies over longer periods of time are
required.
In the DR4tg mouse model of RA, immunization with HomoCitJED did not induce
arthritis. A possible explanation for this finding, is that the DR4tg mice may not have
expressed or expressed insufficient levels of homocitrulline (or citrulline) in their joints.
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Future studies will involve the injection of homocitrullinated or citrullinated antigen into
the knees of DR4tg mice, to provide a target for the immune response and to examine if
this model can recapitulate the disease seen in RA patients.
Furthermore, this study examined the development of cross-reactive immune responses to
a homocitrulline-containing antigen (HomoCitJED).

It is unknown if cross-reactive

immune responses to homocitrulline can develop from an anti-citrulline response. Thus
future studies will examine the induction of anti-citrulline and anti-homocitrulline
responses in mice immunized with CitJED.

4.6 Significance
RA is an inflammatory joint disorder with an unknown etiology, but which is
characterized by antibodies to proteins modified by citrullination. RA patients also
specifically express antibodies to a structural analog of citrulline, homocitrulline. Using
the homocitrulline- and citrulline-rich peptides, HomoCitJED and CitJED, this study
demonstrates that anti-citrulline and anti-homocitrulline antibodies are cross-reactive to
these two amino acids. In addition, this study demonstrated the first in vivo evidence that
the SE is associated with the initiation of immune responses to homocitrulline. Further,
the development of cross-reactive anti-citrulline and anti-homocitrulline immune
responses are dependent on the expression of SE-encoded HLA-DR. A novel mechanism
is presented by which homocitrulline-containing antigens can induce a breakdown in
immunological tolerance to citrullinated self-proteins. Cross-reactive B cells to citrulline
and homocitrulline play a role in propagating autoimmune responses and contribute to
RA pathogenesis. Thus homocitrulline may have an important role in RA development.
Presently, there is no antigen-specific treatment for RA.

The current therapeutic

strategies for RA include the use of immunosuppressants, cytokine inhibitors, and
biologics that target components of the immune system and often have side-effects.
Specific treatment options for RA are being explored. One approach is the use of peptide
vaccines, including citrullinated peptide vaccines, to induce antigen-specific immune
tolerance (32-34). HomoCitJED peptide may also be useful in this approach because this
peptide could potentially block both anti-homocitrulline and anti-citrulline immune
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responses in RA patients. Pilot studies using HomoCitJED peptide to induce tolerance
are ongoing in the Cairns and Bell laboratory.
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Appendices

Appendix 1. Anti-CitJED inhibition by CitJED and HomoCitJED peptides. AntiCitJED inhibition profiles for 15 anti-CCP2 positive (A-O) and 2 anti-CCP2 negative (PQ) RA patients who expressed anti-CitJED and anti-HomoCitJED. Antibodies were
inhibited by various concentrations of either soluble CitJED or HomoCitJED peptide.
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Appendix 2. Anti-HomoCitJED inhibition by CitJED and HomoCitJED peptides.
Anti-HomoCitJED inhibition profiles for 15 anti-CCP2 positive (A-O) and 2 anti-CCP2
negative (P-Q) RA patients (same RA patients as in Appendix 1) who expressed antiCitJED and anti-HomoCitJED. Antibodies were inhibited by various concentrations of
either soluble CitJED or HomoCitJED peptide.
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Appendix 3. Most anti-CitJED and anti-HomoCitJED from single positive RA
patients are cross-reactive. (A-E) Inhibition of anti-CitJED from 5 anti-CitJED single
positive RA patients. (F-J) Inhibition of anti-HomoCitJED from 5 anti-HomoCitJED
single positive RA patients. All patients tested were positive for anti-CCP2; p<0.01 was
considered significant by Two-way ANOVA. n.s. – not significant.

79

D ay 30

D ay 10
B

D R 4 tg # 1

D R 4 tg # 2

*

100

60
40
20
0

80
60
40
20

10 50 75 100 2

10 50 75 100

10 50 75 100 2

2

H o m o C itJ E D

C it J E D

80
60
40
20

10 50 75 100 2

D R 4 tg # 5

C it J E D

F

D R 4 tg # 6

G

0
10 50 75 100 2

C it J E D

10 50 75 100

H o m o C itJ E D

S o lu b le In h ib it o r (  g /m l )

10 50 75 100

H o m o C itJ E D

S o lu b le In h ib it o r (  g /m l )

D R 4 tg # 7

H

60
40
20

*

80
60
40
20
0

2

10 50 75 100 2

C it J E D

D R 4 tg # 8

100

% In h ib it io n

80

0
2

10 50 75 100 2

C it J E D

100

% In h ib it io n

20

2

H o m o C itJ E D

*

100

% In h ib it io n

% In h ib it io n

100

40

20

D ay 70
*

60

40

S o lu b le In h ib it o r (  g /m l )

S o lu b le In h ib it o r (  g /m l )

*

80

60

10 50 75 100

D ay 50
E

80

0
2

10 50 75 100

H o m o C itJ E D

C it J E D

S o lu b le In h ib it o r (  g /m l )

100

0

0
2

D R 4 tg # 4
*

100

% In h ib it io n

80

D

D R 4 tg # 3
*

100

% In h ib it io n

% In h ib it io n

C

*

% In h ib it io n

A

10 50 75 100

H o m o C itJ E D

S o lu b le In h ib it o r (  g /m l )

80
60
40
20
0

2

10 50 75 100 2

C it J E D

10 50 75 100

H o m o C itJ E D

S o lu b le In h ib it o r (  g /m l )

2

10 50 75 100 2

C it J E D

10 50 75 100

H o m o C itJ E D

S o lu b le In h ib it o r (  g /m l )

Appendix 4. Inhibition of anti-HomoCitJED antibodies. Sera from eight HomoCitJED-immunized DR4tg mice (DR4tg #1-8; AH) were used in inhibitions assays at the various days post-immunization as indicated. As measured by direct ELISA, these mice
expressed anti-HomoCitJED antibodies but not anti-CitJED antibodies. The mean percent inhibition of 2 repeats per individual mouse
serum ± the SEM is shown. * - p<0.0001 by Two-way ANOVA with Bonferonni correction.
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Appendix 5. Inhibition of anti-HomoCitJED (black bars) and anti-CitJED (grey bars) antibodies.

Sera from three

HomoCitJED-immunized DR4tg mice (DR4tg #9-11; A-F), were used in inhibitions assays at the various days post-immunization as
indicated. As detected by direct ELISA, these mice were positive for both anti-HomoCitJED and anti-CitJED antibodies. The mean
percent inhibition of 2 repeats per individual mouse serum ± the SEM is shown. * - p<0.0001 by Two-way ANOVA with Bonferonni
correction.
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Appendix 6. Inhibition of anti-HomoCitJED antibodies with HomoCitJED peptide. Inhibition assays were performed on sera
from HomoCitJED-immunized DR4tg and B6 mice.

As measured by direct ELISA, these mice expressed anti-HomoCitJED

antibodies but not anti-CitJED antibodies. The mean percent inhibition (pooled from inhibitions performed on n=4 or 8 mice) ± the
SEM is shown. The p value was determined by Two-way ANOVA with Bonferonni correction.
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Appendix 7. Ethical approval for the use of human samples.
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Appendix 8. Ethical approval for the use of animal subjects.
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